2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts | Westin Copley Place
https://worldmedicalinnovation.org/
https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg
3.1.5 2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts | Westin Copley Place https://worldmedicalinnovation.org/, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair
Announcement
Aviva Lev-Ari, PhD, RN,
Founder and Director of LPBI Group will be in attendance covering the event in REAL TIME
@pharma_BI
@AVIVA1950
4/2018
- Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
- e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point
- Electronic Scientific AGORA: Comment Exchanges by Global Scientists on Articles published in the Open Access Journal @pharmaceuticalintelligence.com – Four Case Studies
All TWEETS from LPBI’s Twitter.com handles at
#WMIF18
Monday, April 23, 2018
GE Foyer
Nuance Foyer
NVIDIA Ballroom
First Look: The Next Wave of AI Breakthroughs in Health Care
Early career Harvard Medical School investigators kick-off the 2018 World Medical Innovation Forum with rapid fire presentations of their high potential new technologies. Nineteen rising stars from Brigham Health and Massachusetts General Hospital will give ten-minute presentations highlighting their discoveries and insights that will disrupt the field of artificial intelligence. This session is designed for investors, leaders, donors, entrepreneurs and investigators and others who share a passion for identifying emerging high-impact technologies. To view speakers and topics, click here.
3rd Floor and 7th Floor
Discovery Café Workshops
Lunch with Top Leadership from across Partners HealthCare and Industry.
Seven intensive workshops addressing cutting-edge artificial intelligence topics. To view topics and speakers, click here
NVIDIA Ballroom
NVIDIA Ballroom
Reflecting on the Impact of AI at the Bed and the Bench: Chairs Roundtable
Senior clinical leaders, current and past Forum Chairs, will share perspectives on the range of impact of AI on clinical practice. Discussion will highlight the rapid evolution of AI as a practical clinical tool and short and mid-term prospects for adoption in cancer, cardiovascular and neurological care.
NVIDIA Ballroom
Can AI Based Drug Development Feed A Hungry Pipeline?
Given the scarcity of late-stage assets, prolonged timelines and enormous costs of bringing drugs to market, AI-based approaches to target discovery, drug design and drug repurposing hold significant promise to positively disrupt the existing R&D paradigm.
NVIDIA Ballroom
Smart EHRs: AI for All
The first wave of EHR adoption has focused primarily on digitizing the patient record – with a more recent focus on building interactive clinical decision support capabilities. Development and implementation of CDS applications currently requires clinical staff to observe trends in data, develop protocols to act on these trends and work with technical staff to codify the logic into executable form. As NLP and computer vision capabilities become more advanced, algorithms will identify and propose actions reflecting patterns in the data. The panel will discuss existing challenges and whether AI technology will ultimately support an unsupervised learning approach in the EHR to identify trends and possible responses at both the patient and population level?
NVIDIA Ballroom
AI and the Cost of Trials: The Impact of Real World and Real Time Evidence
AI based approaches to conduct faster and more efficient clinical trials are beginning to emerge. Current approaches include applying predictive tools to perform more targeted patient recruitment and more accurate eligibility assessment. Panelists will discuss timelines for AI technology to have a measurable effect on trial cost and time to conduct the trial. Bottlenecks to applying this technology at scale and whether there will be a measurable effect on the cost of bringing drugs to market over the next decade will also be examined.
Nuance Foyer
Tuesday, April 24, 2018
Nuance Foyer
NVIDIA Ballroom
NVIDIA Ballroom
Will AI Bend the Cost and Access Curve
Historical barriers have driven increased medical costs and decreasing access since the 1960s. The “Iron Triangle of Healthcare” continues to represent a tenuous balance of quality, cost and accessibility – economists have lamented attempts to optimize one characteristic at the expense of the others. The accumulation of innovations in care delivery (e.g. shift to lower cost providers and settings), population management, value based reimbursement and hospital administration are having a measurable effect. Can AI based technologies accelerate the pace of innovation and finally bend the cost and access curves in the US?
NVIDIA Ballroom
Drug Therapy Redefined Through Machine Learning
The drug development process is highly complex and has many drivers. The panel will discuss the strategic impact of AI on the entire process and the implications for healthcare overall. How will the combination of factors – research strategy, drug development, regulatory approvals, reimbursement and clinical effectiveness – be influenced by the implementation of AI. Panelists will discuss short and mid-term prospects and whether AI will ultimately lead to a restructuring of the pharma model to develop new therapies.
NVIDIA Ballroom
Nuance Foyer
NVIDIA Ballroom
Data Engineering in Healthcare: Liberating Value
The promise of machine learning and big data in in healthcare seems boundless – but healthcare data is massive and complex, and organizing and managing this data is the first step to an AI-empowered healthcare system. Technology giants are investing in solutions to overcome these data engineering challenges, but with many visions of the future of healthcare data jockeying for dominance, what will the future of healthcare data really look like? Can we finally liberate the value of data for patient care? And how will it happen?
NVIDIA Ballroom
1:1 Fireside Chat: Jensen Huang, CEO, NVIDIA
GE Ballroom
GE Ballroom
1:1 Fireside Chat: Paul Ricci, Former Chairman and CEO of Nuance Communications
NVIDIA Ballroom
AI and Gene Sequencing
Gene sequencing technology has evolved considerably over the last 10 years, dramatically decreasing the cost to sequence a human genome. As the costs associated with the technical assay continue to decrease, data interpretation and reporting has become the new bottleneck. Can AI and ML based approaches be applied to better understand how genetic mutations play a role in diseases like cancer – where the high rate of mutation makes treatment challenging? And will continued democratization of genetic information help to accelerate the pace of innovation in the field?
NVIDIA Ballroom
Tangible Returns on the AI Value Proposition
Fueled by billions in venture investments, hundreds of new companies have emerged worldwide to develop and apply AI in health care. Beyond the US, China’s high AI priority has resulted in a vast array of technology driven start-ups. Global investors will discuss which area of machine learning will have the earliest meaningful impact? How do investors critically assess differentiation in such a crowded field? How are investment priorities set among the many divergent categories where AI will take hold?
NVIDIA Ballroom
CEO Roundtable: The AI Opportunity as Foundational Change
Chief executives share perspectives on the impact of AI on their respective companies and industry segments. How prominently does AI figure into current investment strategies? And how are they measuring return on existing investments in AI? Panelist will be asked to take a position on whether AI is a truly transformational technology.
NVIDIA Ballroom
NVIDIA Ballroom
Regulating AI in Healthcare, Requirements and Challenges
The increasing application of AI in health products puts pressure on the historical model of regulation – among them the agile development cycles and continuous learning environment that support AI / machine learning based algorithms. Panelists will discuss the regulatory approaches including the FDA’s recently announced Software Precertification pilot program.
NVIDIA Ballroom
AI in Hospital Environments: The Learning Provider
Health systems are actively evaluating strategies to drive efficiency throughout hospital operations. The deployment of AI based technologies to automate organizational tasks (e.g. medical coding / billing, prior authorizations) and optimize resource utilization (e.g. smart scheduling, no-show prediction) promises to help hospital systems adapt to changing macro-economic factors. This panel will discuss the role of AI in hospital operations and assess various approaches to reduce healthcare administration costs and increase efficiency.
GE Foyer
Wednesday, April 25, 2018
Nuance Foyer
NVIDIA Ballroom
Reconceiving Medical Devices in an AI Dominated Environment
Medical device companies are focused on developing smaller, faster and smarter devices. New technologies will enhance the function of medical devices throughout patient care. Leveraging AI technology to more effectively interact with patients and inform / facilitate outcomes enables smart devices that can learn and improve performance over time. The nature of AI panel based devices, the challenges inherent in developing them and how such devices can evolve over the next 5 years and beyond will be examined.
NVIDIA Ballroom
NVIDIA Ballroom
Fireside Chat: Paying for AI: Thinking Strategically About Reimbursements and Acceptance
Understanding how AI will be absorbed into a highly defined payment system is crucial to determining the rate and breadth that the technology will play in health care in the next decade. Two senior leaders will share their perspectives on how the technology will be paid for and what mechanisms will be used to arbitrate the scope and timing of those payments.
NVIDIA Ballroom
NVIDIA Ballroom
Machine Learning in Image Analysis: A Diagnostician’s Best Friend…or Replacement?
Diagnostic imaging is among the clinical fields receiving the greatest attention in the early stages of AI in healthcare. Even in this initial phase it appears that the technology may have profound effects on one of the most resource intensive fields in medicine. Panelists will consider the broad implications as well as topics such as how will role of radiologists evolve? Will AI tools ever become advanced enough to make decisions autonomously within the clinical workflow?
Nuance Foyer
NVIDIA Ballroom
NVIDIA Ballroom
Illuminating the Path to Clinician Empowerment
The sacred exchange between patient and clinician at the heart of medicine is increasingly under duress driven by a range of factors. Increasing clinician burnout is recognized as among the many negative consequences of this trend. Panelists will discuss how AI may improve the quality of the patient encounter, clinician workflow and ultimately clinician quality of life. Panelist will discuss how the new technology can meet these objectives when earlier information based technologies may have exacerbated the challenge.
NVIDIA Ballroom
Disruptive Dozen: 12 AI Technologies That Will Reinvent Care
The culture of innovation throughout Partners HealthCare naturally fosters robust discussions about new “disruptive” technologies and which ones will have the biggest impact on health care. The Disruptive Dozen was created to identify and rank the technologies that Partners faculty feel will break through over the next decade to significantly improve health care. This year, the Disruptive Dozen focuses on relevant advances and opportunities in artificial intelligence (AI).
NVIDIA Ballroom
*Panels and speakers are subject to change.
Highlighted Presenters
Executive Director, Ariadne Labs; Samuel O. Thier Professor of Surgery, HMS; Surgeon, BWH
Featured Speakers
Associate Director, Early Clinical Development, Respiratory Inflammation & Autoimmunity Therapeutics, AstraZeneca; Former Clinical and Research Fellow, BWH
Director, Beetham Eye Institute, Joslin Diabetes Center, MEE; Vice Chair, Department of Ophthalmology, Professor of Ophthalmology, HMS
Chief Academic Officer, BWH; SVP, Research, BWH; K. Frank Austen Professor of Medicine, HMS
Director of Research Strategy and Operations, MGH & BWH CCDS; Associate Professor, Radiology, HMS
Co-Director, Computation Neuroscience Outcomes Center, Attending Neurosurgeon, Department of Neurosurgery, BWH; Member of the Faculty, HMS
Vice President, Professional Development & Implementation Science, PHS; Assistant Professor of Psychiatry, HMS
Epileptologist, Department of Neurology, MGH; Associate Professor of Neurology, HMS
Faculty Director, Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, HLS
Member of the Faculty of Anaesthesia, BWH; Assistant Professor, Anesthesiology, HMS
Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
Director, Division of Clinical Research, MGH; Associate Dean for Clinical & Translational Research & Professor of Psychiatry, HMS
Executive Director, Ariadne Labs; Samuel O. Thier Professor of Surgery, HMS; Surgeon, BWH
Director, Bioinformatics Program, Cancer Center and Department of Pathology, MGH; Director, Institute Member, Broad Institute; Associate Professor of Pathology, HMS
Neurosurgeon, Director of Image-guided Neurosurgery, BWH; Professor, Neurosurgery, Radiology, HMS
Director, Center for Neurotechnology and Neurorecovery, Neurology, MGH; Senior Lecturer, Neurology, HMS
Director, Center for Genomic Medicine, MGH; Ofer and Shelly Nemirovsky MGH Research Scholar; Associate Professor of Medicine, HMS
Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, HMS; 2018 Forum Co-Chair
Director of Clinical Lab Informatics, Assistant Director Tissue Typing Lab, BWH; Assistant Professor, HMS
Director, Computational Pathology and Director, Technology Development, Center for Integrated Diagnostics, MGH; Assistant Professor, Pathology, HMS
Associate Director, Center for Integrated Diagnostics, MGH; Assistant Professor, Pathology, HMS
Director, Center for Advanced Medical Computing and Analysis, MGH; Associate Professor, Radiology, HMS
Vice Chair for Scientific Innovation, Department of Medicine, BWH; Chief Executive, One Brave Idea, BWH; Associate Professor of Medicine, HMS; 2017 Forum Co-Chair
Associate Director, Healthcare Transformation Lab, MGH; Assistant Professor, Cardiology, HMS
Director of Research, Center for Quantitative Health, MGH; Assistant Professor of Psychiatry & Medicine, HMS
Cheif of Ophthalmology, Massachusetts Eye and Ear and MGH; Chair, Department of Ophthalmology and David Glendenning Cogan Professor of Ophthalmology, HMS
Director, Glaucoma Service and Ophthalmology Telemedicine program, MEE; Professor of Ophthalmology, HMS
Anesthesiologist and Director of Clinical Bioengineering, Department of Anesthesiology, Perioperative and Pain Medicine, BWH; Professor of Anaesthesia, HMS
Chief Data Officer, Broad Institute; Cardiologist, BWH; Venture Partner, Google Ventures
Chair, Department of Anesthesiology, Perioperative and Pain Medicine, BWH; Leroy D. Vandam Professor of Anaesthesia, HMS
Chief Laboratory Director, Laboratory for Molecular Medicine, PHS Personalized Medicine; Associate Professor of Pathology, BWH and HMS
Chief, Cardiology Division, MGH; Professor of Medicine, HMS; 2017 Forum Co-Chair
Co-Director, Applied Chest Imaging Laboratory, BWH; Associate Professor, Radiology, HMS
Director, Laboratory of Micro/Nanomedicine and Digital Health, BWH; Assistant Professor, HMS
Director, Morse Laser Center, Massachusetts Eye and Ear Infirmary; Associate Professor of Ophthalmology, HMS
Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH; Joseph P. and Rose F. Kennedy Professor of Neurology, HMS
Vice Chair of Research at the Department of Radiology, BWH; Ferenc Jolesz MD Professor of Radiology, HMS
Director, MGH Clinical Data Animation Center, MGH; Assistant Professor, HMS
Anesthetist-in-Chief, MGH; Henry Isasiah Dorr Professor of Research and Teaching in Anaesthetics and Anaesthesia, HMS
Chief of Psychology; Director, OCD and Related Disorders Program, MGH; Professor, HMS
Executive Director, Clinical Trials Office, PHS; Associate Professor of Medicine, HMS
Harvard Data Science Postdoctoral Fellow, Department of Biomedical Informatics, HMS
Note: speakers are subject to change.
Leave a Reply